LILRB1 and lymphoma: LILRB1 blockade complemented CD47 inhibition and thus a dual checkpoint blockade of CD47-SIRPα and LILRB1-HLA class I interactions may have the potential to improve antibody therapy of lymphomas further by enhancing ADCP by macrophages.